Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 74

Sort by

Sort Order Select

Journal Articles

The Revised Myeloma Comorbidity Index (R-MCI) As a Promising Approach for Predicting Overall (OS)- and Progression-Free (PFS) Survival and Optimizing Therapy Strategies in Multiple Myeloma (MM) Patients (pts) - Comparative Analysis of 5 Comorbidity Indices (CI), Including Retro- and Prospective Applicability

Katja Schoeller, Gabriele Ihorst, Sophia Scheubeck, Max Holler, Sandra M. Woerner, Heike Reinhardt, Stefan P. Müller, Justus Duyster, MD, Ralph Wäsch, MD, Monika Engelhardt, MD

Blood (2019) 134 (Supplement_1): 3474.

https://doi.org/10.1182/blood-2019-127030

Published: 2019

Journal Articles

Expanding on Current Definitions of Hematologic Improvement in MDS, CMML and AML: Landmark Analyses of 1301 Patients Treated with Azacitidine in the Austrian Registry of Hypomethylating Agents By the AGMT-Study Group

Blood (2019) 134 (Supplement_1): 3821.

https://doi.org/10.1182/blood-2019-128153

Published: 2019

Journal Articles

CUL1: Novel Therapeutic Target in Myeloid Neoplasms Harboring -7/Del(7q)

Blood (2019) 134 (Supplement_1): 1281.

https://doi.org/10.1182/blood-2019-129196

Published: 2019

Journal Articles

Aceruloplasminemia and Paroxysmal Nocturnal Hemoglobinuria Uncover Differential Expressions of Ceruloplasmin and Ferroportin in Immune Cells

Marina Borges, BSc,MSc, Marina Dal'Bó Pelegrini Campioni, BSc, Dulcinéia Martins de Albuquerque, PhD, Carolina Lanaro, PhD, Fernando F. Costa, MD, PhD, Kleber Yotsumoto Fertrin, MD PhD

Blood (2018) 132 (Supplement 1): 4895.

https://doi.org/10.1182/blood-2018-99-113485

Published: 2018

Journal Articles

Clinical Application of Epigenetic Modifier Mutations in Myeloma

Gareth J. Morgan

Blood (2018) 132 (Supplement 1): SCI-39.

https://doi.org/10.1182/blood-2018-99-109524

Published: 2018

Journal Articles

Persistence of Somatic Mutation Spectrum and Clonal Architecture in Chronic Myelomonocytic Leukemia Treated with Hypomethylating Agents

Hein Than, MD FRCPath, MRCP, Yi Qiao, PhD, Xiaomeng Huang, PhD, Dongqing Yan, Jamshid Sorouri Khorashad, MD PhD FRCPath, Anthony D. Pomicter, MS, Anca Franzini, PhD, Tibor Kovacsovics, Thomas O'Hare, PhD, Gabor T. Marth, DSc, Michael W. Deininger, MD PhD

Blood (2017) 130 (Supplement 1): 2527.

https://doi.org/10.1182/blood.V130.Suppl_1.2527.2527

Published: 2017

Journal Articles

Systemic Mastocytosis with Associated Acute Myeloid Leukemia (SM-AML): a Poor-Risk Multi-Mutated Disease That Follows a Distinct Diagnostic Algorithm and Requires High-Dose Stem Cell-Targeting Therapy

Blood (2017) 130 (Supplement 1): 2916.

https://doi.org/10.1182/blood.V130.Suppl_1.2916.2916

Published: 2017

Journal Articles

Correlation of Myelodysplasia-Related Flow Cytometric Findings with Mutations in Patients Undergoing Diagnostics for Suspected Myelodysplastic Syndrome

Wolfgang Kern, MD, Manja Meggendorfer, PhD, Annette Fasan, PhD, Claudia Haferlach, MD, Torsten Haferlach, MD

Blood (2017) 130 (Supplement 1): 2969.

https://doi.org/10.1182/blood.V130.Suppl_1.2969.2969

Published: 2017

Journal Articles

Microenvironment-Specific Activation of Notch2 in Splenic Marginal Zone Lymphoma

Vignesh Shanmugam, MD, Scott B Lovitch, MD, PhD, Karim A. Benhadji, Gerald J. Oakley, MD, Jon C. Aster, MD PhD

Blood (2017) 130 (Supplement 1): 1485.

https://doi.org/10.1182/blood.V130.Suppl_1.1485.1485

Published: 2017

Journal Articles

High Levels of Hematopoietic Progenitors in the Fetal Lung Enable Induction of Immune Tolerance and Co-Transplantation of Epithelial Progenitors for Repair of Lung Injury Across MHC Barriers

Carmit Hillel Karniel, MSc, Chava Rosen, MD PhD, Esther Bachar Lustig, PhD, Elias Shezen, PhD, Yair Reisner, PhD

Blood (2016) 128 (22): 1477.

https://doi.org/10.1182/blood.V128.22.1477.1477

Published: 2016

Journal Articles

Incidence and Prognostic Impact of Cytogenetics in Combination with Molecular Aberrations in Patients with Systemic Mastocytosis

Nicole Naumann, Mohamad Jawhar, MD, Juliana Schwaab, MD, Georgia Metzgeroth, MD, Henning D Popp, MD, Nada Khaled, MD, Hans-Peter Horny, MD, Karl Sotlar, MD, Peter Valent, MD, Claudia Haferlach, MD, Gudrun Göhring, MD, Brigitte Schlegelberger, Prof, MD, Manja Meggendorfer, PhD, Nicholas C.P. Cross, PhD, Wolf-Karsten Hofmann, MD, Andreas Reiter, MD, Alice Fabarius, PhD

Blood (2016) 128 (22): 947.

https://doi.org/10.1182/blood.V128.22.947.947

Published: 2016

Journal Articles

Next Generation Veto Cells for Non-Myeloablative Haploidentical HSCT: Combining Anti-Viral and Graft Facilitating Activity

Esther Bachar Lustig, PhD, Noga Or Geva, PhD, Assaf Lask, PhD, Rotem Gidron, MD, Sivan Kagan, PhD, Aloukick Kumar Sinqh, PhD, Yair Reisner, PhD

Blood (2016) 128 (22): 3345.

https://doi.org/10.1182/blood.V128.22.3345.3345

Published: 2016

Journal Articles

Accumulation of the NPM-1 Splice Variant R2 Accompanies AML Development

Krzysztof Giannopoulos, MD PhD, Malgorzata Zajac, PhD, Olga Jankowska-Lecka, PhD, Joanna Zaleska, Joanna Purkot, Tomasz Gromek, MD, Maria Soroka-Wojtaszko, MD PhD, Aneta Szudy-Szczyrek, MD, Marek Hus, MD PhD, Lars Bullinger, MD

Blood (2015) 126 (23): 2590.

https://doi.org/10.1182/blood.V126.23.2590.2590

Published: 2015

Journal Articles

Differential Diagnosis of Hereditary and Acquired Thrombocytopenia By the Immature Platelet Fraction and Thrombopoietin Levels

Fabio Luiz Bandeira Ferreira, Marina Pereira Colella, MD PhD, Samuel de Souza Medina, MD, Maiara Marx Luz Fiusa, Loredana Nilkenes Gomes da Costa, Carolina Costa-Lima, MD, Fernanda Andrade Orsi, MDPhD, Joyce Maria Annichino-Bizzacchi, MD PhD, Kleber Yotsumoto Fertrin, MD PhD, Maria de Fatima Pereira Gilberti, MD, Margareth C Ozelo, Erich Vinicius De Paula, MD PhD

Blood (2015) 126 (23): 1049.

https://doi.org/10.1182/blood.V126.23.1049.1049

Published: 2015

Journal Articles

Prediction of Venous Thromboembolism in Patients with Cancer By the Activated Partial Thromboplastin Time: Results from the Vienna Cancer and Thrombosis Study

Cihan Ay, MD, Florian Posch, MDMSc, Julia Riedl, MD, Oliver Koenigsbruegge, MD, Peter Quehenberger, MD, Christoph Zielinski, MD, Ingrid Pabinger, MD

Blood (2015) 126 (23): 653.

https://doi.org/10.1182/blood.V126.23.653.653

Published: 2015

Journal Articles

Hydroxyurea Is Most Suitable for Cytoreduction of AML Prior to CD33/CD3 Bispecific BiTE® Antibody (AMG 330) Therapy: Uncompromised T-Cell Proliferation Ex-Vivo and CD33 Upregulation on AML Cells

Christina Krupka, Franziska Brauneck, Felix S Lichtenegger, MD, Peter Kufer, MD, Roman Kischel, MD, Gerhard Zugmaier, Thomas Köhnke, MD, Torben Altmann, MD, Stephanie Schneider, PhD, Michael Fiegl, MD, Karsten Spiekermann, MD, Angus M Sinclair, PhD, Kathryn J Newhall, PhD, Stanley R Frankel, MD, Patrick Baeuerle, PhD, Wolfgang Hiddemann, MD, Gert Riethmüller, MD, Marion Subklewe, MD

Blood (2014) 124 (21): 986.

https://doi.org/10.1182/blood.V124.21.986.986

Published: 2014

Journal Articles

Clonal Evolution in Relapsed or Refractory Diffuse Large B Cell Lymphoma

Thomas Melchardt, MD, Clemens Hufnagl, MSC, Oliver Weigert, MD, David M. Weinstock, MD, Nadja Kopp, MA, Lukas Weiss, MD PhD, Daniel Neureiter, MD, Wolfgang Tränkenschuh, MD, Hubert Hackl, Dr, Richard Greil, MD, Alexander Egle, MD

Blood (2014) 124 (21): 77.

https://doi.org/10.1182/blood.V124.21.77.77

Published: 2014

Journal Articles

In Analogy to AML, MDS Can be Sub-Classified By Ancestral Mutations

Blood (2014) 124 (21): 823.

https://doi.org/10.1182/blood.V124.21.823.823

Published: 2014

Journal Articles

Unique and Potent Tumor Specific Antibodies in Graft Versus Leukemia Responses

Marijn A. Gillissen, MD, Etsuko Yasuda, PhD, Sophie Levie, Arjen Q Bakker, Martijn Kedde, Yvonne B Claassen, Cynthia Huisman, MD PhD, Hergen Spits, PhD, Tim Beaumont, PhD, Mette D. Hazenberg, MD PhD

Blood (2014) 124 (21): 3826.

https://doi.org/10.1182/blood.V124.21.3826.3826

Published: 2014

Journal Articles

Characterization of the Short RNA Transcriptome of the Anucleate Platelet

Eric R. Londin, PhD, Phillipe Loher, BS, Leonard C. Edelstein, PhD, Kathy Delgrosso, Paolo M. Fortina, MD PhD, Paul F Bray, MD, Steven E. McKenzie, MD PhD, Isidore Rigoutsos, PhD

Blood (2014) 124 (21): 4990.

https://doi.org/10.1182/blood.V124.21.4990.4990

Published: 2014

NARROW

Expanding on Current Definitions of Hematologic Improvement in MDS, CMML and AML: Landmark Analyses of 1301 Patients Treated with Azacitidine in the Austrian Registry of Hypomethylating Agents By the AGMT-Study Group

CUL1: Novel Therapeutic Target in Myeloid Neoplasms Harboring -7/Del(7q)

Aceruloplasminemia and Paroxysmal Nocturnal Hemoglobinuria Uncover Differential Expressions of Ceruloplasmin and Ferroportin in Immune Cells

Clinical Application of Epigenetic Modifier Mutations in Myeloma

Persistence of Somatic Mutation Spectrum and Clonal Architecture in Chronic Myelomonocytic Leukemia Treated with Hypomethylating Agents

Systemic Mastocytosis with Associated Acute Myeloid Leukemia (SM-AML): a Poor-Risk Multi-Mutated Disease That Follows a Distinct Diagnostic Algorithm and Requires High-Dose Stem Cell-Targeting Therapy

Correlation of Myelodysplasia-Related Flow Cytometric Findings with Mutations in Patients Undergoing Diagnostics for Suspected Myelodysplastic Syndrome

Microenvironment-Specific Activation of Notch2 in Splenic Marginal Zone Lymphoma

High Levels of Hematopoietic Progenitors in the Fetal Lung Enable Induction of Immune Tolerance and Co-Transplantation of Epithelial Progenitors for Repair of Lung Injury Across MHC Barriers

Incidence and Prognostic Impact of Cytogenetics in Combination with Molecular Aberrations in Patients with Systemic Mastocytosis

Next Generation Veto Cells for Non-Myeloablative Haploidentical HSCT: Combining Anti-Viral and Graft Facilitating Activity

Accumulation of the NPM-1 Splice Variant R2 Accompanies AML Development

Differential Diagnosis of Hereditary and Acquired Thrombocytopenia By the Immature Platelet Fraction and Thrombopoietin Levels

Prediction of Venous Thromboembolism in Patients with Cancer By the Activated Partial Thromboplastin Time: Results from the Vienna Cancer and Thrombosis Study

Hydroxyurea Is Most Suitable for Cytoreduction of AML Prior to CD33/CD3 Bispecific BiTE® Antibody (AMG 330) Therapy: Uncompromised T-Cell Proliferation Ex-Vivo and CD33 Upregulation on AML Cells

Clonal Evolution in Relapsed or Refractory Diffuse Large B Cell Lymphoma

In Analogy to AML, MDS Can be Sub-Classified By Ancestral Mutations

Unique and Potent Tumor Specific Antibodies in Graft Versus Leukemia Responses

Characterization of the Short RNA Transcriptome of the Anucleate Platelet

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only